



LEVIN PAPANTONIO RAFFERTY

Proctor | Buchanan | O'Brien
Barr | Mougey | P.A.

KIMBERLY LAMBERT ADAMS
KATHRYN L. AVILA
BRIAN H. BARR
MICHAEL C. BIXBY
BRANDON L. BOGLE
W. TROY BOUK
WESLEY A. BOWDEN
VIRGINIA M. BUCHANAN
JEFF R. GADDY
RACHAEL R. GILMER
BRENTON J. GOODMAN
JOSHUA R. HARRIS
S. MATTHEW KEEN
MARTIN H. LEVIN
ROBERT M. LOEHR

STEPHEN A. LUONGO
M. JUSTIN LUSKO
NEIL E. McWILLIAMS, JR.
JULIA A. METTS
PETER J. MOUGEY
DANIEL A. NIGH
TIMOTHY M. O'BRIEN
MIKE PAPANTONIO
SARA T. PAPANTONIO
CHRISTOPHER G. PAULOS
EMMIE J. PAULOS
MADELINE E. PENDLEY
A. RENEE PRESTON
ROBERT E. PRICE
MARK J. PROCTOR

TROY A. RAFFERTY
MATTHEW D. SCHULTZ
W. CAMERON STEPHENSON
THOMAS A. TAYLOR
REBECCA K. TIMMONS
BRETT VIGODSKY

RETIRED:
M. ROBERT BLANCHARD
CLAY MITCHELL

OF COUNSEL:
WILLIAM F. CASH III
LAURA S. DUNNING
(LICENSED ONLY IN ALABAMA)

BEN W. GORDON, JR.
ARCHIE C. LAMB, JR.
LARUBY MAY
CARISSA PHELPS
(LICENSED ONLY IN CALIFORNIA)
PAGE A. POERSCHKE
(LICENSED ONLY IN ALABAMA)
CHRISTOPHER V. TISI
(LICENSED ONLY IN WASHINGTON, D.C.
AND MARYLAND)
LEFFERTS L. MABIE, JR. (1925-1996)
D.L. MIDDLEBROOKS (1926-1997)
DAVID H. LEVIN (1928-2002)
STANLEY B. LEVIN (1938-2009)
FREDRIC G. LEVIN (1937-2021)

March 24, 2022

Via Email

zOpioidSFNonstayedDefs@skaddenlists.com

Re: In re National Prescription Opiate Litigation, MDL 2804
Plaintiff's FRE 1006 Summary Exhibits – Track Four

Dear Counsel:

Pursuant to the Court's Order re Trial Protocols and Deadlines entered on February 1, 2022 (Dkt. # 1004) and the Joint Trial Exhibit and Witness Stipulation agreed to by the parties (Dkt. # 1048), the People are providing summaries, charts, and/or calculations that the People may introduce at trial pursuant to Federal Rule Evidence 1006 ("Rule 1006 Summaries"). Set forth below is a listing of the underlying material summarized by each Rule 1006 Summary, the exhibit numbers of the underlying materials summarized, and a brief explanation of the manner in which the documents and/or data were summarized, and the person through whom the People expect to introduce the summaries.

Plaintiff reserves the right to modify these Rule 1006 Summaries, including but not limited to, changing the titles, formatting, or presentation, as well to reflect changes in the litigation, including to account for Defendants who settle, are severed, or otherwise are no longer present at trial. Plaintiff reserves the right to identify and produce additional Rule 1006 Summaries at a later date, as contemplated by the Joint Trial Exhibit and Witness Stipulation. Plaintiff reserves the right to identify and produce additional Rule 1006 Summaries prior to and during trial in rebuttal to Defendants' presentation at trial. Demonstrative exhibits and charts, including those contained in previously exchanged expert reports are not included here.

A. McCANN SUMMARIES

The People expect to introduce the Rule 1006 Summaries described below through Dr. Craig McCann. Additional information concerning many of these Rule 1006 Summaries is contained in the October 5, 2021, Expert Report of Dr. Craig McCann, the October 26, 2021, Supplemental Expert Report of Dr. Craig McCann, the December 23, 2021, Rebuttal Report of Dr. Craig McCann and/or the February 18, 2022, Second Supplemental Expert Report of Dr. Craig McCann.

1. DISTRIBUTION SUMMARIES

Plaintiff's Exhibits **P-29831** through **P-28836**; **P-29878**; **P-29873**; and **P-28476** are summaries of the Drug Enforcement Administration's ("DEA") Automation of Reports and Consolidated Orders System ("ARCOS") data produced by the DEA, associated government data, and distribution transaction data produced by the Defendants. The documents and data used to prepare these summaries are as follows:

- **P-23640** - ARCOS data produced by the DEA



- **P-23212, P-28509 and P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco
- **P-43623** - “NDC/NHRIC Labeler Codes,” U.S. Food & Drug Administration, January 2018
- **P-43624** - “Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors,” Centers for Disease Control and Prevention, August 2017
- **P-43625** - “Full Replacement Monthly NPI File,” Centers for Medicare and Medicaid Services, December 2019
- **P-28519** - Data published by the United States Census Bureau
- **P-43621 and P-23211** - “National Drug Code Dictionary,” Drug Enforcement Administration, accessed in November 2018 and January 2020
- **P-23645** - “NDC Dictionary Instructions,” Drug Enforcement Administration, October 2010
- Defendants’ Distribution Data
 - **P-24406** - Anda_Opioid_CA_SF-Tx-Data-SF_0000001
 - **P-24483** - Anda_Opioid_CA_SF-Tx-Data-SF_0000002
 - **P-28513** - WAGCAS00000002; WAGCAS00000006
 - **P-28514** - ABDC-SF-FED00000001 - ABDC-SF-FED00000011, ABDC-SF-FED00001215, ABDC-SF-FED00001225 - ABDC-SF-FED00001226, ABDC-SF-FED00001247 - ABDC-SF-FED00001288
 - **P-28515** - CAH_FEDSF_0000011_HIGHLY CONFIDENTIAL
 - **P-28516** - MCK-SF-00000003_HIGHLY CONFIDENTIAL
 - **P-28578** - TEVA_NY_01019779 - TEVA_NY_01019863

2. RETAIL DRUG SUMMARY REPORT SUMMARIES

Plaintiff’s Exhibit **P-29830** is a summary of the DEA’s ARCOS Retail Drug Summary Reports (“RDSR”) for the years 1997 - 2019. The DEA publishes six RDSRs each year, which summarize the weight of opioids reported in ARCOS transactions by various combinations of Drug Code, Calendar Quarter, Buyer State, Buyer Zip Code, or Buyer’s business activity. The RDSRs are public records of the DEA that set out matters the DEA has a legal duty to report. The RDSR Summaries also contains a map showing the three-digit zip codes included in the RDSR Summary. The RDSRs used to create the RDSR Summaries are publicly available on the DEA’s website¹, and are as follows:

- **P-23649** “ARCOS Retail Drug Summary Reports,” DEA, 1997
- **P-23650** “ARCOS Retail Drug Summary Reports,” DEA, 1998
- **P-23651** “ARCOS Retail Drug Summary Reports,” DEA, 1999
- **P-23560** “ARCOS Retail Drug Summary Reports,” DEA, 2000
- **P-23561** “ARCOS Retail Drug Summary Reports,” DEA, 2001
- **P-23563** “ARCOS Retail Drug Summary Reports,” DEA, 2002
- **P-23564** “ARCOS Retail Drug Summary Reports,” DEA, 2003

¹ available at www.dea diversion.usdoj.gov/arcos/retail drug summary/index.html.

- **P-23607** “ARCOS Retail Drug Summary Reports,” DEA, 2012 - Report 5
- **P-23608** “ARCOS Retail Drug Summary Reports,” DEA, 2012 - Report 7
- **P-23609** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 1
- **P-23610** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 2
- **P-23611** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 3
- **P-23612** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 4
- **P-23613** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 5
- **P-23614** “ARCOS Retail Drug Summary Reports,” DEA, 2013 - Report 7
- **P-23615** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 1
- **P-23616** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 2
- **P-23617** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 3
- **P-23618** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 4
- **P-23619** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 5
- **P-23620** “ARCOS Retail Drug Summary Reports,” DEA, 2014 - Report 7
- **P-23621** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 1
- **P-23622** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 2
- **P-23623** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 3
- **P-23624** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 4
- **P-23625** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 5
- **P-23626** “ARCOS Retail Drug Summary Reports,” DEA, 2015 - Report 7
- **P-23627** “ARCOS Retail Drug Summary Reports,” DEA, 2016
- **P-23628** “ARCOS Retail Drug Summary Reports,” DEA, 2017
- **P-23652** “ARCOS Retail Drug Summary Reports,” DEA, 2018
- **P-23175** “ARCOS Retail Drug Summary Reports,” DEA, 2019
- **P-28464** “ARCOS Retail Drug Summary Reports,” DEA, 2020

3. DISPENSING SUMMARIES

Plaintiff’s Exhibits **P-29837** and **P-29853** are summaries of the Walgreens Dispensing Data produced in this action. The Dispensing Data is composed of prescriptions, with each line of data containing basic information about the prescriber, the dispensed drug, the dispensed quantity, the dispensing pharmacy and the patient receiving the prescription. The Dispensing Data also provides the date and time when the prescription was filled and the date when the prescription was written. The data provided by Walgreens includes prescriptions on 8 opioid molecules: hydrocodone, oxycodone, morphine, fentanyl, methadone, tapentadol, hydromorphone and oxymorphone. The data also reflects benzodiazepine and muscle relaxer prescriptions dispensed to any patient who also received an opioid prescription whenever the benzodiazepine or muscle relaxer prescription was dispensed within 14 days of the opioid prescription. The documents and data used to create the Dispensing Summaries are as follows:

- **P-28518** WAGSFDATA00001 - WAGSFDATA00003

4. DISTRIBUTION AND DISPENSING SUMMARY

Plaintiff’s Exhibits **P-29838** and **P-29839** are summaries of the ARCOS data produced by the DEA and Walgreens Dispensing Data produced by Defendants. For each Defendant, these

summaries show the total dosage units and/or MME distributed to the Defendant on a monthly basis as reflected in ARCOS and the total amount dispensed by that same Defendant as reflected in that Defendant's Dispensing data. The documents and data used to create the Distribution and Dispensing Summaries are those used to create the ARCOS Distribution Summaries as outlined in section A.1 above and the those used to create the Dispensing Summary as outlined in section A.3 above.

5. MANUFACTURER MARKET SHARE SUMMARIES

Plaintiff's Exhibits **P-29840** through **P-29848** are summaries of the of the ARCOS data produced by the DEA. For each Defendant, these summaries show shipments to Dispensers in the ARCOS Data traced upstream to Manufacturers using NDC codes and manufacturer's discovery responses and supplemental productions as listed below. The documents and data used to create the Manufacturer Market Share summaries are:

- **P-23640** - ARCOS data produced by the DEA;
- **P-23212**, **P-28509** and **P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco;
- **P-43623** - "NDC/NHRIC Labeler Codes," U.S. Food & Drug Administration, January 2018;
- **P-43624** - "Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors," Centers for Disease Control and Prevention, August 2017;
- **P-43621** and **P-23211** - "National Drug Code Dictionary," Drug Enforcement Administration, accessed in November 2018 and January 2020;
- **P-23645** - "NDC Dictionary Instructions," Drug Enforcement Administration, October 2010;
- **P-28578** - TEVA_NY_01019779 - TEVA_NY_01019863;
- **P-28579** - Teva_NY – Summary Direct and Indirect Sales Data – CONFIDENTIAL.xlsx, October 22, 2021;
- **P-28583** - Compilation of Manufacturer (Allergan Specific) Produced Files for NDC Allergan Amended Objections and Responses to Plaintiff's Interrogatories (03/20/2019, all cases; 05/31/2019 Response, Cuyahoga & Summit; 07/30/2019, Cuyahoga & Summit) and supporting files (ALLERGAN_MDL_01852265 - ALLERGAN_MDL_01852266);
- **P-28586** - Compilation of Manufacturer (Endo Specific) Produced Files for NDC, Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's Third Set of Interrogatories (01/07/2019, Cleveland, Cuyahoga & Summit) and supporting files (ENDO_DATA-OPIOID_MDL-00000017 - ENDO_DATA-OPIOID_MDL-00000041);
- **P-28587** - Compilation of Manufacturer (Par Specific) Produced Files for NDC, Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.'s Second Supplemental Objections and Responses to Plaintiff's Interrogatory Nos. 5, 22, 23, 24, 27, and 33 (06/27/2019, Cleveland, Cuyahoga & Summit) and supporting files (PAR_OPIOID_MDL_0001596806 - PAR_OPIOID_MDL_0001596819; PAR_OPIOID_MDL_0001596821 - PAR_OPIOID_MDL_0001596826; PAR_OPIOID_MDL_0002016639 - PAR_OPIOID_MDL_0002016785);
- **P-28642** - Compilation of Manufacturer (Teva/Actavis/Cephalon Specific) Produced Files for NDC, Teva Defendants' Supplemental Responses and Objections

to Plaintiff's First Set of Interrogatories (09/17/2021, City & County of San Francisco), 09/24/2021 Letter from Harvey Bartle, and supporting files (TEVA_MDL_A_02401117; TEVA_MDL_A_02416192; TEVA_MDL_A_02416205; TEVA_MDL_A_02416208; TEVA_MDL_A_02419959 - TEVA_MDL_A_02419960; TEVA_MDL_A_02419962 - TEVA_MDL_A_02419969; TEVA_MDL_A_08637279)

6. WALGREENS TARGET DRUG GOOD FAITH DISPENSING CHECKLIST SUMMARY

Plaintiff's Exhibit **P-29849** is a summary of the Walgreens Target Drug Good Faith Dispensing Checklists ("TDGFD Checklists") for Walgreens stores in San Francisco, which were produced by Walgreens in this action. Beginning in April 2013, Walgreens required its pharmacists to complete a TDGFD Checklist for every prescription presented to the pharmacist for certain "Target Drugs."² The "Target Drugs" are limited to single ingredient oxycodone, hydromorphone, and methadone.³ When presented with a Target Drug prescription, pursuant to Walgreens's policies, the pharmacist and technician must complete a TD GFD checklist as part of the pharmacist's evaluation of whether to fill the target drug prescription.⁴ The TDGFD Checklist summary shows the number of TDGFD Checklists produced per individual Walgreens store and the corresponding number of prescriptions for oxycodone, hydromorphone, and methadone filled by that store. The TDGFD summary only summarizes those TDGFD checklists that were for prescriptions of single ingredient oxycodone, hydromorphone, and methadone. The documents and data used to create the Walgreens TDGFD summary are as follows:

- **P-28518** - Walgreens Dispensing Data WAGSFDATA00001 - WAGSFDATA00003
- **P-28542** - Composite Exhibit of Walgreens TDGFD Checklists

7. WALGREENS SUSPICIOUS CONTROL DRUG ORDER REPORTS SUMMARIES

Plaintiff's Exhibit **P-29850** is a summary of Walgreens Suspicious Control Drug Order Reports. Walgreens used the Suspicious Control Drug Order Reports to report certain shipments of controlled substances to the DEA until 2012.⁵ Walgreens has produced Suspicious Control Drug Order Reports for its stores nationwide.⁶ The Walgreens Suspicious Control Drug Order Reports summary summarizes the Walgreens CT4 store orders appearing on the Walgreens Suspicious Control Drug Order Reports and compares that to the n. The documents and data used to create the Walgreens Suspicious Control Drug Order Reports summaries are as follows:

- **P-28540** –Walgreens Suspicious Control Drug Order Report Composite

² Ex. **P-17177** (WAGMDL00316360 - National TD GFD Compass Communication); Ex. **P-17188** (WAGMDL00744586 - Walgreens National TD-GFD Policy (Updated FAQs); NATIONAL TARGET DRUG (TD) GOOD FAITH DISPENSING (GFD) FAQs).

³ Ex. **P-15037** (WAGMDL00001237 at 1246 - Target Good Faith Dispensing Policy Revised 9/23/2013); Ex. **P-15038** (WAGMDL00001151 – Target Good Faith Dispensing Policy Revised 5/24/2016).

⁴ Ex. **P-15310** (WAGMDL00674951 at WAGMDL00674989 - TD GFD High Level Process).

⁵ See, Walgreens Second Supplemental Responses to Plaintiffs' (First) Combined Discovery Requests to the National Retail Pharmacies Defendants for Track One Cases at pg. 15.

⁶ See, Walgreens Third Supplemental Responses and Objections to Plaintiffs' First Set of Track Three Interrogatories at pg. 15.

- **P-28521** – Walgreens Processed Distribution Data
- **P-28513** – Walgreens Distribution Transactional Data

8. WALGREENS ELECTRONIC NOTES SUMMARIES

Plaintiff's Exhibits **P-28539** and **P-29852** are summaries of Electronic Notes, Scanned Prescriptions and Related Documents provided by Walgreens for the 2,265 sample prescriptions and Electronic Notes appended to the patient history of prescriptions filled by 12 Walgreens stores (#1126, #11385, #1327, #13666, #13668, #2088, #4318, #4558, #4609, #5487, #5599, and #7044, collectively as "12 Walgreens Stores") in San Francisco County, CA. The documents and data used to create these summaries are as follows:

- **P-28518** – Walgreens Dispensing Data - WAGSFDATA00001 - WAGSFDATA00003
- **P-28512** – Walgreens Electronic Notes Composite - WAGSFDATA00004 - WAGSFDATA00020
- **P-28527** - WAG Hard Copy Scripts - Composite of Walgreens Store 01126 - WAGCASF00309584 - WAGCASF00309678; WAGCASF00309682 - WAGCASF00310020; WAGCASF00310974 - WAGCASF00311219; WAGCASF00333506 - WAGCASF00333515
- **P-28528** - WAG Hard Copy Scripts - Composite of Walgreens Store 01327 – WAGCASF00310039 - WAGCASF00310073; WAGCASF00310078 - WAGCASF00310098; WAGCASF00310101 - WAGCASF00310144; WAGCASF00311289 - WAGCASF00311533; WAGCASF00312435 - WAGCASF00312565; WAGCASF00312569 - WAGCASF00312780; WAGCASF00333563 - WAGCASF00333661; WAGCASF00333931 - WAGCASF00333948
- **P-28529** - WAG Hard Copy Scripts - Composite of Walgreens Store 02088 - WAGCASF00311670 - WAGCASF00311729; WAGCASF00312781 - WAGCASF00312895; WAGCASF00333662 - WAGCASF00333815; WAGCASF00334418 - WAGCASF00334553; WAGCASF00335281 - WAGCASF00335325
- **P-28530** - WAG Hard Copy Scripts - Composite of Walgreens Store 04318 - WAGCASF00312896 - WAGCASF00312952; WAGCASF00333816 - WAGCASF00333830; WAGCASF00334301
- **P-28531** - WAG Hard Copy Scripts - Composite of Walgreens Store 04558 - WAGCASF00310021 - WAGCASF00310038; WAGCASF00311220 - WAGCASF00311236; WAGCASF00333516 - WAGCASF00333521; WAGCASF00334554 - WAGCASF00334562
- **P-28532** - WAG Hard Copy Scripts - Composite of Walgreens Store 04609 WAGCASF00310263 - WAGCASF00310413; WAGCASF00311730 - WAGCASF00311788; WAGCASF00312953 - WAGCASF00313291
- **P-28533** - WAG Hard Copy Scripts - Composite of Walgreens Store 05487 WAGCASF00310414 - WAGCASF00310480; WAGCASF00311789 -

WAGCASF00312379; WAGCASF00313292 - WAGCASF00313300;
WAGCASF00334302 - WAGCASF00334417

- **P-28534** - WAG Hard Copy Scripts - Composite of Walgreens Store 05599
WAGCASF00311237 - WAGCASF00311288; WAGCASF00333831 -
WAGCASF00333930; WAGCASF00334563 - WAGCASF00334597
- **P-28535** - WAG Hard Copy Scripts - Composite of Walgreens Store 07044
WAGCASF00312380 - WAGCASF00312434; WAGCASF00333491 -
WAGCASF00333505; WAGCASF00334598 - WAGCASF00334621
- **P-28536** - WAG Hard Copy Scripts - Composite of Walgreens Store 11385
WAGCASF00313301 - WAGCASF00314273; WAGCASF00333522 -
WAGCASF00333562; WAGCASF00334622 - WAGCASF00334983
- **P-28537** - WAG Hard Copy Scripts - Composite of Walgreens Store 13666
WAGCASF00311534 - WAGCASF00311580; WAGCASF00334984 -
WAGCASF00335115; WAGCASF00335326 - WAGCASF00335565
- **P-28538** - WAG Hard Copy Scripts - Composite of Walgreens Store 13668
WAGCASF00310145 - WAGCASF00310262; WAGCASF00311581 -
WAGCASF00311669; WAGCASF00333949 - WAGCASF00334300;
WAGCASF00335116 - WAGCASF00335280
- **P-28542** - Composite Exhibit of Walgreens TDGFD Checklists

Plaintiff's Exhibit **P-29851** is a summary of Walgreens Electronic Notes Fields and Walgreens Electronic Notes. The documents and data used to create the Walgreens Electronic Notes Fields and Walgreens Electronic Notes Summary are as follows:

- **P-28512** - WAGSFDATA00004 - WAGSFDATA00020
- **P-17236** - WAGNMAG00053391 - WAGNMAG00053392
- **P-17237** - WAGMDL00790910

9. ANDA DISTRIBUTION SUMMARIES

A. Anda ARCOS Summaries

Plaintiff's Exhibits **P-29854** through **P-29859** and **P-29864** through **P-29869** are summaries of ARCOS data.

Plaintiff's Exhibits **P-29854** and **P-29864** are summaries of ARCOS Data reflecting all Anda shipments to Bryant Rank Prepack.

Plaintiff's Exhibit **P-29855** and **P-29865** are summaries of ARCOS Data reflecting all Anda shipments to Dispensing Solutions.

Plaintiff's Exhibit **P-29856** and **P-29866** are summaries of ARCOS Data reflecting all Anda shipments to Aidarex Pharmaceuticals LLC.

Plaintiff's Exhibit **P-29857** and **P-29867** are summaries of ARCOS Data reflecting all Anda shipments to Harvard Drug Group.

Plaintiff's Exhibit **P-29858** and **P-29868** are summaries of ARCOS Data reflecting all Anda shipments to Southwood Pharmaceuticals Inc.

Plaintiff's Exhibit **P-29859** and **P-29869** are summaries of ARCOS Data reflecting all Anda shipments to HJ Harkins.

The documents and data used to create the Anda Distribution Summaries marked as Plaintiff's Exhibits **P-29854** through **P-29859** and **P-29864** through **P-29869** are as follows:

- **P-23212**, **P-28509** and **P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco

B. Anda Shipments Attributed to Manufacturers

Plaintiff's Exhibit **P-29870** is a summary of Anda shipments of opioids into San Francisco, reflected in ARCOS Data, that were attributable to each manufacturer, based on NDC provided by Manufacturer Defendants' Responses to Plaintiffs' Interrogatories and cross-checked by ARCOS. This summary also reflects each manufacturer's ratio as a percentage of the dosage units of all Anda shipments into San Francisco and each manufacturer's ratio as a percentage of the dosage units of all opioid shipments that were attributable to this manufacturer. The documents and data used to create this summary are as follows:

- **P-23212**, **P-28509** and **P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco
- **P-24406** - Anda_Opioid_CA_SF-Tx-Data-SF_0000001
- **P-24483** - Anda_Opioid_CA_SF-Tx-Data-SF_0000002
- **P-28521** –Anda Processed Distribution Data
- **P-43621** and **P-23211** - "National Drug Code Dictionary," Drug Enforcement Administration, accessed in November 2018 and January 2020
- **P-23645** - "NDC Dictionary Instructions," Drug Enforcement Administration, October 2010
- **P-28578** - TEVA_NY_01019779 - TEVA_NY_01019863
- **P-28579** - Teva_NY – Summary Direct and Indirect Sales Data – CONFIDENTIAL.xlsx, October 22, 2021
- **P-28583** - Compilation of Manufacturer (Allergan Specific) Produced Files for NDC Allergan Amended Objections and Responses to Plaintiff's Interrogatories (03/20/2019, all cases; 05/31/2019 Response, Cuyahoga & Summit; 07/30/2019, Cuyahoga & Summit) and supporting files (ALLERGAN_MDL_01852265 - ALLERGAN_MDL_01852266)
- **P-28586** - Compilation of Manufacturer (Endo Specific) Produced Files for NDC, Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's' Third Set of Interrogatories (01/07/2019, Cleveland,

Cuyahoga & Summit) and supporting files (ENDO_DATA-OPIOID_MDL-00000017 - ENDO_DATA-OPIOID_MDL-00000041)

- **P-28587** - Compilation of Manufacturer (Par Specific) Produced Files for NDC, Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.'s Second Supplemental Objections and Responses to Plaintiff's Interrogatory Nos. 5, 22, 23, 24, 27, and 33 (06/27/2019, Cleveland, Cuyahoga & Summit) and supporting files (PAR_OPIOID_MDL_0001596806 - PAR_OPIOID_MDL_0001596819; PAR_OPIOID_MDL_0001596821 - PAR_OPIOID_MDL_0001596826; PAR_OPIOID_MDL_0002016639 - PAR_OPIOID_MDL_0002016785)
- **P-28642** - Compilation of Manufacturer (Teva/Actavis/Cephalon Specific) Produced Files for NDC, Teva Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (09/17/2021, City & County of San Francisco), 09/24/2021 Letter from Harvey Bartle, and supporting files (TEVA_MDL_A_02401117; TEVA_MDL_A_02416192; TEVA_MDL_A_02416205; TEVA_MDL_A_02416208; TEVA_MDL_A_02419959 - TEVA_MDL_A_02419960; TEVA_MDL_A_02419962 - TEVA_MDL_A_02419969; TEVA_MDL_A_08637279)

Plaintiff's Exhibit **P-29871** is a summary of Anda shipments of opioids into San Francisco, as reflected in ARCOS Data, that were attributable to each manufacturer, based on NDC provided by Manufacturer Defendants' Responses to Plaintiffs' Interrogatories and cross-checked by ARCOS. The documents and data used to create this summary are as follows:

- **P-23212**, **P-28509** and **P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco
- **P-24406** - Anda_Opioid_CA_SF-Tx-Data-SF_0000001
- **P-24483** - Anda_Opioid_CA_SF-Tx-Data-SF_0000002
- **P-28521** - Anda Processed Distribution Data
- **P-43621** and **P-23211** - "National Drug Code Dictionary," Drug Enforcement Administration, accessed in November 2018 and January 2020
- **P-23645** - "NDC Dictionary Instructions," Drug Enforcement Administration, October 2010
- **P-28578** - TEVA_NY_01019779 - TEVA_NY_01019863
- **P-28579** - Teva_NY - Summary Direct and Indirect Sales Data - CONFIDENTIAL.xlsx, October 22, 2021
- **P-28583** - Compilation of Manufacturer (Allergan Specific) Produced Files for NDC Allergan Amended Objections and Responses to Plaintiff's Interrogatories (03/20/2019, all cases; 05/31/2019 Response, Cuyahoga & Summit; 07/30/2019, Cuyahoga & Summit) and supporting files (ALLERGAN_MDL_01852265 - ALLERGAN_MDL_01852266)
- **P-28586** - Compilation of Manufacturer (Endo Specific) Produced Files for NDC, Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's Third Set of Interrogatories (01/07/2019, Cleveland,

Cuyahoga & Summit) and supporting files (ENDO_DATA-OPIOID_MDL-00000017 - ENDO_DATA-OPIOID_MDL-00000041)

- **P-28587** - Compilation of Manufacturer (Par Specific) Produced Files for NDC, Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.'s Second Supplemental Objections and Responses to Plaintiff's Interrogatory Nos. 5, 22, 23, 24, 27, and 33 (06/27/2019, Cleveland, Cuyahoga & Summit) and supporting files (PAR_OPIOID_MDL_0001596806 - PAR_OPIOID_MDL_0001596819; PAR_OPIOID_MDL_0001596821 - PAR_OPIOID_MDL_0001596826; PAR_OPIOID_MDL_0002016639 - PAR_OPIOID_MDL_0002016785)
- **P-28642** - Compilation of Manufacturer (Teva/Actavis/Cephalon Specific) Produced Files for NDC, Teva Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (09/17/2021, City & County of San Francisco), 09/24/2021 Letter from Harvey Bartle, and supporting files (TEVA_MDL_A_02401117; TEVA_MDL_A_02416192; TEVA_MDL_A_02416205; TEVA_MDL_A_02416208; TEVA_MDL_A_02419959 - TEVA_MDL_A_02419960; TEVA_MDL_A_02419962 - TEVA_MDL_A_02419969; TEVA_MDL_A_08637279)

C. Anda ARCOS and Distribution Data

Plaintiff's Exhibits **P-29860** through **P-29863** are summaries of ARCOS Data and Anda Transactional Data.

Plaintiff's Exhibit **P-29860** is a summary of Anda shipments to Four Fifty Sutter Pharmacy.

Plaintiff's Exhibit **P-29861** is a summary of Anda shipments to Visitacion Valley Pharmacy.

Plaintiff's Exhibit **P-29862** is a summary of Anda shipments to Reliable Drug.

Plaintiff's Exhibit **P-29863** is a summary of Anda shipments to Lucky Pharmacy #756.

The documents and data used to create this summary are as follows:

- **P-23212, P-28509** and **P-28510** - ARCOS data as processed by Dr. McCann for the U.S., California and San Francisco
- **P-24406** - Anda_Opioid_CA_SF-Tx-Data-SF_0000001
- **P-28521** - Anda Processed Distribution Data

10. CALIFORNIA CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM (CURES) SUMMARIES

Plaintiff's Exhibits **P-29874** through **P-29877** are summaries of dispensing data contained in the California Controlled Substance Utilization Review and Evaluation System ("CURES") database. The CURES platform tracks all Schedule II – V controlled substances dispensed to patients in California. The California Department of Justice produced certain CURES data statewide for years 2012 through the first quarter of 2021.

Plaintiff's Exhibit **P-29874** is a summary of CURES Data that sets out the number of prescriptions, patients and dosage units and MME in San Francisco.

Plaintiff's Exhibit **P-29875** is a summary of CURES Data that shows the opioid market share of selected San Francisco pharmacies.

Plaintiff's Exhibit **P-29876** is a summary of CURES Data that shows the total prescriptions written by selected prescribers and the number of those prescriptions filled at Walgreens and Non-Walgreens pharmacies.

Plaintiff's Exhibit **P-29877** is a summary of CURES Data that shows the total number of prescriptions filled, the average number of prescriptions filled monthly, the total dosage units of prescriptions filled and the average dosage units of prescriptions filled monthly, for selected pharmacies.

The data used to create the CURES summaries is as follows:

- **P-29828** - Database/Data Set: CURES Data

B. MATTHEW PERRI / PRZEMYSŁAW JEZIORSKI SUMMARIES

The People expect to introduce the Rule 1006 Summaries described below through Matthew Perri and/or Przemyslaw Jeziorski.

1. SIR SPEEDY SUMMARY

Plaintiff's Exhibit **P-29898** is a summary of materials ordered for or by San Francisco Bay Area Endo sales representatives via "Sir Speedy" for distribution to health care providers. In each sheet, the materials were filtered to include only orders for sales representatives who logged Opana ER calls to Bay Area Prescribers and shipped to an address within San Francisco. A pivot table was used to create the total number of each material dropped as well the first and last dates dropped. In the table "Misleading Documents Dropped", the Materials have also been filtered by those with known false or misleading statements. The documents and data used to create the Sir Speedy Summary are as follows:

- **P-28951** - ENDO_SF-00589717
- **P-19895** - ENDO_SF-00500952
- ECF 1017 – Stipulation Regarding the Use of Certain Documents and Discovery and Exhibits A, B and E thereto.

2. MATERIALS DROPPED SUMMARY

Plaintiff's Exhibit **P-29899** is a summary of materials San Francisco Bay Area sales representatives reported dropping during calls to local health care providers. Documents dropped in each "Materials Dropped" data file were filtered for materials dropped in the Bay Area. A pivot table was used to create the total number of each material dropped as well the first and last dates dropped. The documents and data used to create the Materials Dropped Summary are as follows:

- P-20085 - ENDO-CA-00164788
- P-24523 - ENDO-OPIOID_MDL-07391961
- P-24280 - ENDO ENDO_DATA-OPIOID_MDL-00000100

- P-24301 - ENDO ENDO_DATA-OPIOID_MDL-0000010
- P-16985 - ENDO-OPIOID_MDL-08000578
- P-20583 - ENDO-OPIOID_MDL-07391955
- P-20584 - ENDO-OPIOID_MDL-07391957
- P-24541 - ENDO-OPIOID_MDL-08526231
- ECF 1017 – Stipulation Regarding the Use of Certain Documents and Discovery and Exhibits A, B and E thereto.

3. NIPC SUMMARY

Plaintiff's Exhibit **P-29900** is a summary of programs presented by Endo-sponsored NIPC in San Francisco and was prepared by reviewing the documents listed below for NIPC events occurring in San Francisco. The documents and data used to create the NIPC Summary are as follows:

- **P-20549** - KP360_OHIOMDL_000284014
- **P-20714** - KP360_OHIOMDL_000360625
- **P-20713** - KP360_OHIOMDL_000354126
- **P-20781** - KP360_OHIOMDL_000365156
- **P-29569** - KP360_OHIOMDL_000177737
- **P-20368** - KP360_OHIOMDL_000177776
- **P-29566** - KP360_OHIOMDL_000377990
- **P-20516** - KP360_OHIOMDL_000239739
- **P-20529** - KP360_OHIOMDL_000273155
- **P-20130** - KP360_OHIOMDL_000056336
- **P-29574** - KP360_OHIOMDL_000072946
- **P-20103** - KP360_OHIOMDL_000002773
- **P-20109** - KP360_OHIOMDL_000028501
- **P-20114** - KP360_OHIOMDL_000028505
- **P-29572** - KP360_OHIOMDL_000029092
- **P-20149** - KP360_OHIOMDL_000082053
- **P-20214** - KP360_OHIOMDL_000092815
- **P-20218** - KP360_OHIOMDL_000115612
- **P-20364** - KP360_OHIOMDL_000132694
- **P-29568** - KP360_OHIOMDL_00162639
- **P-12609** - KP360_OHIOMDL_000336756
- **P-29571** - ENDO_ANK_CHI_0490880
- **P-20715** - KP360_OHIOMDL_000363678
- **P-20369** - KP360_OHIOMDL_000178305
- **P-20106** - KP360_OHIOMDL_000003337
- **P-20117** - KP360_OHIOMDL_000032767
- **P-20115** - KP360_OHIOMDL_000028535
- **P-29573** - KP360_OHIOMDL_000033236
- **P-29575** - KP360_OHIOMDL_000082232

- **P-20216** - KP360_OHIOMDL_000092939
- **P-20121** - KP360_OHIOMDL_000038986
- **P-18637** - KP360_OHIOMDL_000081713
- **P-20178** - KP360_OHIOMDL_000092649
- **P-18628** - ENDO_FLAG-00463412
- **P-18633** - ENDO_SF-00482201
- **P-20364** - KP360_OHIOMDL_000132694
- **P-10655** - END00662274
- **P-29567** - CHI_001207848
- **P-29570** - KP360_OHIOMDL_000336620

C. WEITZ & LUXENBERG, PC, LEGAL ASSISTANT SHIRIN KHAN SUMMARIES

To the extent that more than a declaration is needed to explain the creation of the exhibits listed below, the People expect to introduce these Rule 1006 Summaries described below through a legal assistant employed by Weitz & Luxenberg, PC, Shirin Khan.

1. MASTER SUMMARY OF ANDA SUSPICIOUS ORDER REPORTS, 2007-2007

Plaintiff's Exhibit P-29576 is a compilation of "Suspicious Order Reports" produced by Anda, Inc. in the MDL and listed on either Plaintiff's or Defendants' Exhibit Lists for the years 2005-2007, the exhibit numbers and bates numbers of the underlying documents are included in the summary. The summary was created by Shirin Khan, a legal assistant employed by Weitz & Luxenberg, PC by combining the identified excel documents of each suspicious order spreadsheet into one master spreadsheet. The Exhibit contains the following columns:

- A. Bates Source – this is the bates number of the spreadsheet from which the data was extracted and imported into the master.
- B. Duplicate Bates – these bates numbers represent duplicates of the "Bates Source" document that were listed on the exhibit lists of either Anda, Inc., Plaintiff, or both.
- C. Plaintiff Exhibit No. – these are the Plaintiff's branded trial exhibit numbers of the "Bates Source" and "Duplicate Bates" numbers
- D. Anda Exhibit No. – these are the Defendant, Anda, Inc.'s branded trial exhibit numbers of the "Bates Source" and "Duplicate Bates" numbers
- E. All other columns in the spreadsheet are as presented in the original source documents.

2. CUSTOMER SPECIFIC EXTRACTIONS OF THE MASTER SUMMARY OF SUSPICIOUS ORDER REPORTS

Plaintiff's Exhibits **P-29577** through **P-29582** are extractions from the Master Summary of Suspicious Order Reports for reports related to each of the following Anda customers:

- A. Bryant Ranch Prepack (**P-29577**)
- B. Dispensing Solutions, Inc. (**P-29578**)
- C. H. J. Harkins Company, Inc. (**P-29579**)
- D. Harvard Drug Group (**P-29580**)
- E. Southwood Pharmaceuticals, Inc. (**P-29581**)
- F. Specialty Pharmacy, Inc. (**P-29582**)

D. TEVA SUSPICIOUS ORDER REPORT SUMMARIES

To the extent that more than a declaration is needed to explain the creation of the exhibits listed below, the People expect to introduce these Rule 1006 Summaries described below through an associate employed by Skikos, Crawford, Skikos & Joseph LLP, Uzair Saleem.

1. MASTER SUMMARY OF TEVA SUSPICIOUS ORDER REPORTS THROUGH 2018

Plaintiff's Exhibit P-____ is a summary chart of all 28 "Suspicious Order Reports" sent from Teva to the DEA through 2018. These reports were produced by Teva Pharmaceuticals in the MDL, and identified in the Teva Defendants' January 7, 2019 Responses and Objections of Defendants to Plaintiffs' Third Set of Interrogatories, Response to No. 32, and Appendix A thereto (identifying all suspicious order reports to the DEA). The summary was created by Uzair Saleem, an associate employed by Skikos, Crawford, Skikos & Joseph LLP, by compiling all the reports listed in Appendix A of Teva's January 7, 2019 interrogatory responses, identifying the unique reports and separating them from the numerous duplicate reports identified in Appendix A, and identifying the data from those 28 unique reports that are referenced in the summary chart the People seek to introduce. The 28 non-duplicative reports utilized for the P-____ summary chart are compiled in Exhibit P-27871, and consist of the non-duplicative documents identified by Bates number in Appendix A to Teva's interrogatory responses.

Sincerely,

A handwritten signature in black ink, appearing to read "Page Poerschke". The signature is fluid and cursive, with a large loop at the beginning and a long horizontal stroke at the end.

Page Poerschke